Clinical pharmacology of new H-1-receptor antagonists, and why it matters

There are many new H-1-receptor antagonists. Their clinical pharmacology, a s objectively measured in pharmacokinetic and pharmacodynamic studies, diff ers considerably The importance of understanding these differences should n ot be underestimated, as they directly influence H-1-antagonist dose and do se interval, and they facilitate H-1-antagonist use in special populations, for example, the elderly. Without a doubt, pharmacokinetic and pharmacodyn amic studies of H-1-antagonists provide a scientific foundation for using t hese medications with optimal effectiveness and safety.